Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
- The demands on tissue specimens from diagnostic stains and PD-L1 testing may leave little remaining for genomic profiling
- Gaps in genomic biomarker testing can be overcome with new technologies
“Liquid biopsy could help rescue patients who cannot receive genotype testing because of insufficient tissue.”
Martin E. Gutierrez, MD
John Theurer Cancer Center
In this prospective analysis of 193 advanced cancer patients profiled with the Guardant360 assay, the objective response rate for patients in the NSCLC arm who were matched to targeted therapy was 87%.
The disease control rate was 100%.
- This prospective study demonstrated the clinical utility of using ctDNA to guide treatment selection in advanced cancer patients
- A quarter of the patients in the NSCLC cohort were matched to targeted therapy
- Median overall survival more than doubled (31.8 vs. 12.7 months) with targeted therapy compared to non-targeted cytotoxic therapy